Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV

the Taiwan HIV Study Group

doi:10.1093/cid/ciad730

Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV

the Taiwan HIV Study Group

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background. Real-world experience with combinations of short-course rifapentine-based regimens and integrase strandtransfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods. From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens. Results. During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate. Conclusions. Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.

Original language	English
Pages (from-to)	1295-1303
Number of pages	9
Journal	Clinical Infectious Diseases
Volume	78
Issue number	5
DOIs	https://doi.org/10.1093/cid/ciad730
Publication status	Published - 2024 May 15

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciad730

Fingerprint

Dive into the research topics of 'Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV'. Together they form a unique fingerprint.

Cite this

@article{c78db1a820c4413594a3f7f042d30613,

title = "Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV",

abstract = "Background. Real-world experience with combinations of short-course rifapentine-based regimens and integrase strandtransfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods. From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens. Results. During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate. Conclusions. Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.",

author = "{the Taiwan HIV Study Group} and Lin, {Kuan Yin} and Sun, {Hsin Yun} and Yang, {Chia Jui} and Lu, {Po Liang} and Lee, {Yuan Ti} and Lee, {Nan Yao} and Liou, {Bo Huang} and Tang, {Hung Jen} and Lee, {Mei Hui} and Wang, {Ning Chi} and Chen, {Tun Chieh} and Hii, {Ing Moi} and Huang, {Sung Hsi} and Lin, {Chi Ying} and Tsai, {Chin Shiang} and Cheng, {Chien Yu} and Hung, {Chien Ching} and Chang, {Sui Yuan} and Huang, {Yu Shan} and Chen, {Guan Jhou} and Wu, {Pei Ying} and Chen, {Ling Ya} and Chang, {Hsi Yen} and Liu, {Wen Chun} and Su, {Yi Ching} and Lin, {Te Yu} and Tsai, {Mao Song} and Lee, {Yi Chieh} and Cheng, {Shu Hsing} and Huang, {Yi Chia} and Peng, {An Ting} and Lee, {Yu Lin} and Lin, {Chia Chun} and Lin, {Shih Ping} and Hsieh, {Chia Yin} and Wang, {Hsiu Wen} and Ho, {Mao Wang} and Liu, {Chun Eng} and Hung, {Tung Che} and Chen, {Yen Hsu} and Lee, {Chun Yuan} and Tsai, {Hung Chin} and Lin, {Hsi Hsun} and Lee, {Chen Hsiang}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2024",

month = may,

day = "15",

doi = "10.1093/cid/ciad730",

language = "English",

volume = "78",

pages = "1295--1303",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV. / the Taiwan HIV Study Group.
In: Clinical Infectious Diseases, Vol. 78, No. 5, 15.05.2024, p. 1295-1303.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV

AU - the Taiwan HIV Study Group

AU - Lin, Kuan Yin

AU - Sun, Hsin Yun

AU - Yang, Chia Jui

AU - Lu, Po Liang

AU - Lee, Yuan Ti

AU - Lee, Nan Yao

AU - Liou, Bo Huang

AU - Tang, Hung Jen

AU - Lee, Mei Hui

AU - Wang, Ning Chi

AU - Chen, Tun Chieh

AU - Hii, Ing Moi

AU - Huang, Sung Hsi

AU - Lin, Chi Ying

AU - Tsai, Chin Shiang

AU - Cheng, Chien Yu

AU - Hung, Chien Ching

AU - Chang, Sui Yuan

AU - Huang, Yu Shan

AU - Chen, Guan Jhou

AU - Wu, Pei Ying

AU - Chen, Ling Ya

AU - Chang, Hsi Yen

AU - Liu, Wen Chun

AU - Su, Yi Ching

AU - Lin, Te Yu

AU - Tsai, Mao Song

AU - Lee, Yi Chieh

AU - Cheng, Shu Hsing

AU - Huang, Yi Chia

AU - Peng, An Ting

AU - Lee, Yu Lin

AU - Lin, Chia Chun

AU - Lin, Shih Ping

AU - Hsieh, Chia Yin

AU - Wang, Hsiu Wen

AU - Ho, Mao Wang

AU - Liu, Chun Eng

AU - Hung, Tung Che

AU - Chen, Yen Hsu

AU - Lee, Chun Yuan

AU - Tsai, Hung Chin

AU - Lin, Hsi Hsun

AU - Lee, Chen Hsiang

PY - 2024/5/15

Y1 - 2024/5/15

N2 - Background. Real-world experience with combinations of short-course rifapentine-based regimens and integrase strandtransfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods. From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens. Results. During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate. Conclusions. Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.

AB - Background. Real-world experience with combinations of short-course rifapentine-based regimens and integrase strandtransfer inhibitor-containing antiretroviral therapy (ART) in management of latent tuberculous infection (LTBI) is limited among people with human immunodeficiency virus (PWH). Methods. From August 2019 to October 2022, PWH receiving 3 months of weekly rifapentine plus isoniazid (3HP) or 1 month of daily rifapentine plus isoniazid (1HP) in combination with ART were included. The primary outcome was virologic response within 12 months after LTBI treatment; secondary outcomes included treatment completion rate and safety of LTBI regimens. Results. During the study period, 479 PWH (94.6% male; median age, 43 years) were included: 142 received 1HP and bictegravir (BIC)-containing regimens (1HP/BIC group), 46 1HP and dolutegravir (DTG)-containing regimens (1HP/DTG group), 38 3HP and BIC-containing regimens (3HP/BIC group), 214 3HP and DTG-containing regimens (3HP/DTG group), 17 1HP and other ART regimens (1HP/others group), and 22 3HP/other ART regimens (3HP/others group). In the intention-to-treat analysis, the proportions of PWH maintaining plasma HIV-1 RNA <200 copies/mL within 12 months after LTBI treatment completion were 96.5% (1HP/BIC), 100% (1HP/DTG), 100% (3HP/BIC), 95.8% (3HP/DTG), 100% (1HP/others), and 100% (3HP/others). The overall completion rates were >80% for all treatment groups, whereas >50% of the included PWH experienced any adverse event. LTBI regimens and ART combinations were not associated with virologic response and completion rate. Conclusions. Combinations of short-course rifapentine-based regimens and integrase strand-transfer inhibitor-containing ART maintained viral suppression for most PWH within 12 months of LTBI treatment completion with low rates of grade 3 or higher adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85193310939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85193310939&partnerID=8YFLogxK

U2 - 10.1093/cid/ciad730

DO - 10.1093/cid/ciad730

M3 - Article

C2 - 38051646

AN - SCOPUS:85193310939

SN - 1058-4838

VL - 78

SP - 1295

EP - 1303

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination with Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection among People with HIV

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this